Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, Uttar Pradesh, 221005, India.
Nanomedicine (Lond). 2022 May;17(12):913-934. doi: 10.2217/nnm-2021-0389. Epub 2022 Apr 22.
Inflammatory lung disorders have become one of the fastest growing global healthcare concerns, with more than 500 million annual cases of disorders such as chronic obstructive pulmonary disease, asthma and pulmonary fibrosis. Owing to environmental changes and socioeconomic disparity, the numbers are expected to grow even more in years to come. The therapeutic strategies and approved drugs currently employed in the management of inflammatory lung disorders show dose-dependent resistance and pharmacokinetic limitations. This review comprehensively discusses lipid-based pulmonary nanomedicine as a potential platform to overcome these barriers while ensuring site-specific drug delivery and minimal side effects in nontargeted tissues for the management of noninfectious inflammatory lung disorders.
炎性肺疾病已成为全球增长最快的医疗保健问题之一，每年有超过 5 亿例慢性阻塞性肺疾病、哮喘和肺纤维化等疾病。由于环境变化和社会经济差距，预计未来几年这一数字还会增加。目前用于治疗炎性肺疾病的治疗策略和批准药物显示出剂量依赖性耐药性和药代动力学限制。本综述全面讨论了基于脂质的肺部纳米医学作为一种潜在平台，以克服这些障碍，同时确保在非靶向组织中具有特定部位的药物递送和最小的副作用，从而管理非传染性炎性肺疾病。
